Posts Tagged: "COVID-19 Research"

mRNA IP and Competitive Landscape: 2021 in Review – Part II, Sanofi, Startups, Conclusions and Outlook

This article, originally published on 12/27/2021, was updated on 1/12/2022 and republished on 1/13/2022 to include information that was omitted in error, beginning after “Conclusions and Outlook”.

In Part I of this post, we provided an update on three lead pioneers in the mRNA IP space, Moderna, BioNTech and CureVac. In this post we profile Sanofi, Arcturus, eTheRNA and other mRNA companies and offer conclusions. Sanofi (NASDAQ: SNY), headquartered in Paris, FR, acquired mRNA pioneer Translate Bio in September 2021 for approximately $3.2 billion and mRNA startup Tidal Therapeutics in April 2021 for approximately $470 million. With its acquisition of Translate alone, Sanofi obtained an mRNA pipeline of nine candidates (two in the clinic), hundreds of patents, and undoubtedly valuable mRNA-based technical and regulatory know-how.

Dan Shores & Vivian Y. Tian & Sheena X. Wang

January 13, 2022

Tillis and Blackburn Introduce Anti-Hacking Bill Aimed at Protecting COVID-19 Vaccine Research

The Defend COVID Research from Hackers Act was introduced on Tuesday by Senators Thom Tillis (R-NC) and Marsha Blackburn (R-TN) with the goal of authorizing the President to “take swift action and add sanctions to countries trying to disrupt or hack COVID-19 research.” This bill is the Senate companion to legislation introduced in the House of Representatives in July by House Minority Leader Kevin McCarthy (R-CA).

IPWatchdog

October 7, 2020